Department of Biology, College of Sciences, University of Ha'il, Hail 2440, Saudi Arabia.
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Ha'il, Hail 2440, Saudi Arabia.
Molecules. 2021 Mar 11;26(6):1549. doi: 10.3390/molecules26061549.
Considering the urgency of the COVID-19 pandemic, we developed a receptor-based pharmacophore model for identifying FDA-approved drugs and hits from natural products. The COVID-19 main protease (M) was selected for the development of the pharmacophore model. The model consisted of a hydrogen bond acceptor, donor, and hydrophobic features. These features demonstrated good corroboration with a previously reported model that was used to validate the present model, showing an RMSD value of 0.32. The virtual screening was carried out using the ZINC database. A set of 208,000 hits was extracted and filtered using the ligand pharmacophore mapping, applying the lead-like properties. Lipinski's filter and the fit value filter were used to minimize hits to the top 2000. Simultaneous docking was carried out for 200 hits for natural drugs belonging to the FDA-approved drug database. The top 28 hits from these experiments, with promising predicted pharmacodynamic and pharmacokinetic properties, are reported here. To optimize these hits as M inhibitors and potential treatment options for COVID-19, bench work investigations are needed.
考虑到 COVID-19 大流行的紧迫性,我们开发了一种基于受体的药效团模型,用于识别美国食品和药物管理局批准的药物和天然产物中的命中化合物。选择 COVID-19 主蛋白酶 (M) 来开发药效团模型。该模型由氢键受体、供体和疏水特征组成。这些特征与之前报道的模型很好地吻合,该模型用于验证本模型,显示 RMSD 值为 0.32。使用 ZINC 数据库进行虚拟筛选。使用配体药效团映射提取并过滤了一组 208,000 个命中化合物,应用类药性属性。使用 Lipinski 过滤器和拟合值过滤器将命中化合物减少到前 2000 个。同时对属于美国食品和药物管理局批准药物数据库的 200 种天然药物进行了 200 次对接。报告了这些实验中具有有前途的预测药效动力学和药代动力学特性的前 28 个命中化合物。为了优化这些作为 M 抑制剂的命中化合物,并作为 COVID-19 的潜在治疗选择,需要进行实验室研究。